# Italy's antitrust authority says it has opened an investigation into drug maker Biogen Italia and its parent Biogen over alleged abuse of dominant position.

*biotech · news · 2026-05-27 · MarketScreener*

## Key points

- Italy's antitrust authority is investigating Biogen Italia and Biogen for abusing market dominance.
- The investigation concerns attempts to exclude Sandoz from selling natalizumab-based multiple sclerosis drugs.
- Italian regulators, with finance police, have already conducted inspections at Biogen's Italian offices.
- Biogen has not yet issued a statement or comment in response to the investigation.

MILAN, May 27 (Reuters) - Italy's antitrust authority said on Wednesday it had opened an investigation into drug maker Biogen Italia and its parent Biogen over alleged abuse of dominant position. The two companies allegedly aimed at excluding rival Sandoz from offering multiple sclerosis drugs, based on active ingredient natalizumab, the regulator said in a statement. The watchdog carried out inspections at Biogen's Italian offices, assisted by Italy's finance police, it added. Biogen was not immediately available for comment. (Reporting by Cristina Carlevaro, editing by Giulia Segreti)

**Companies:** Biogen Italia, Biogen
**Countries:** Italy

[Read the full story on MarketScreener](https://www.marketscreener.com/news/italy-s-antitrust-regulator-opens-probe-into-us-biogen-over-alleged-dominant-position-ce7f5ad2de88f224)

---

Canonical: https://newsio.io/n/d9ca70fa-f4f1-494b-b049-475be0124604/italys-antitrust-authority-says-it-has-opened-an-investigation-into-drug-maker-b
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works